brolucizumab; brolucizumab-dbll (Beovu)
Jump to navigation
Jump to search
Indications
- wet age-related macular degeneration[2]
- diabetic macular edema[3]
Dosage
- 6 mg, intravitreal injection every 4 weeks
- 0.05 mL brolucizumab-dbll 120 mg/mL injection [Beovu]
Clinical significance
- clinically similar visual outcomes vs aflibercept[3]
Mechanism of action
- VEGF inhibitor (humanized monoclonal antibody)
More general terms
References
- ↑ RxNorm
- ↑ 2.0 2.1 Wikipedia: Brolucizumab https://en.wikipedia.org/wiki/Brolucizumab
- ↑ 3.0 3.1 3.2 Singh RP, Barakat MR, Ip MS et al Efficacy and Safety of Brolucizumab for Diabetic Macular Edema. The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. Published online November 16, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37971723 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2811933